Eton Pharmaceuticals, Inc.
Eton Pharmaceuticals, Inc. (Nasdaq: ETON) develops and commercializes treatments for rare diseases, including prescription drugs and medical formulas for patients with endocrine and metabolic conditions. Its eight commercial products include INCRELEX for severe primary IGF-1 deficiency, ALKINDI SPRINKLE and KHINDIVI… From the company’s description.
Over the twelve months to Sep 30, 2026, Eton Pharmaceuticals, Inc. reported revenue of $141.06M, up 100.6% from a year earlier, and net income of $49.86M. Its operating margin was 28.8%, and operations generated $38.35M in cash. In fiscal 2025, it reported revenue of $79.95M, up 104.9% from fiscal 2024, and a net loss of $4.60M.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Eton Pharmaceuticals, Inc. does
In the company’s own words
Eton Pharmaceuticals, Inc. (Nasdaq: ETON) develops and commercializes treatments for rare diseases, including prescription drugs and medical formulas for patients with endocrine and metabolic conditions. Its eight commercial products include INCRELEX for severe primary IGF-1 deficiency, ALKINDI SPRINKLE and KHINDIVI for adrenal insufficiency, GALZIN for Wilson disease, PKU GOLIKE for phenylketonuria, and generic treatments for NAGS deficiency, homocystinuria and tyrosinemia type 1. The company also has five late-stage product candidates addressing conditions including diabetes insipidus, neonatal diabetes, Wilson disease, adrenal insufficiency and adrenal crisis. Eton sells its U.S. products through specialty pharmacies, supported by its own sales and marketing organization and patient services. It relies on contract manufacturers for production. At December 31, 2025, Eton had 44 full-time employees, including 24 in sales and marketing and 12 in research and development. Its portfolio combines products acquired or licensed from other companies with internally developed candidates. Its website is www.etonpharma.com.
Company details
- Sector
- Health Care
- Industry (SIC)
- Pharmaceutical Preparations
- Headquarters
- DEER PARK, IL
- Fiscal year end
- December
- CIK
- 1710340
- SIC
- 2834
Financial performance, year by year
Fiscal 2018–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Eton Pharmaceuticals, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Superinvestors in Eton Pharmaceuticals, Inc. · what they did last quarter
Share of each manager’s reported 13F portfolio. Change is in shares held, since the previous quarter.
Largest fund holders · Eton Pharmaceuticals, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Fund ownership is a subset of institutional 13F ownership — the two describe overlapping populations and must not be added together.
Could not be determined for this company: bond issues.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Eton Pharmaceuticals, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Eton Pharmaceuticals, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Eton Pharmaceuticals, Inc.'s last four quarterly filings that the numbers alone won't show?”